Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 2/2022

14-04-2022 | NSCLC | review

Highlights ESMO 2021—lung cancer

Author: Dr. Markus Rauter

Published in: memo - Magazine of European Medical Oncology | Issue 2/2022

Login to get access

Summary

The following three abstracts presented at EESMO 2021 highlight three different areas of therapeutic strategies for non small cell lung cancer. First, neoadjuvant Atezolizumab managed to show a superior DFS compared to best supportive care in completely resected NSCLC stage II–IIIA. Second, Cemiplimab combined with chemotherapy reached the primary endpoint of OS compared to chemo alone in advanced stage IIIB/C & stage IV NSCLC patients. Third, the BEVERLY trial showed that the combination of Erlotinib with Bevacizumab in advanced EGFR-mutated NSCLC prooved to be superior to Erlotinib monotherapy in the current/former smoker subgroup, suggesting that this subgroup represents a differnt tumor biology with sprecial therapeutic needs.
Literature
1.
Felip E, et al. Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB–IIIA NSCLC. In: Presidential symposium 3; September 20th, 2021. Presentation LBA9. Annals of Oncology 2021;32(suppl_5):S1283–346. https://​doi.​org/​10.​1016/​annonc/​annonc741.CrossRef
2.
3.
Altorki N, Felip E, Zhou C, et al. IMpower010: characterization of stage IB–IIIA NSCLC patients by type and extent of therapy prior to adjuvant atezolizumab. In: International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer; September 8–14, 2021; virtual. Abstract PL02.05.
4.
Zhou C, et al. IMpower010: biomarkers of disease-free survival (DFS) in a Phase 3 study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB–IIIA NSCLC. In: Proffered Paper session 1; 2O – IMpower010; December 9th, 2021. Annals of Oncology 2021;32(suppl_7):S1373–91. https://​doi.​org/​10.​1016/​annonc/​annonc784.CrossRef
5.
Gogishvili M, et al. Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC). In: Mini oral session – NSCLC, metastatic; September 19th, 2021. Presentation LBA51. Annals of Oncology 2021;32(suppl_5):S1283–346. https://​doi.​org/​10.​1016/​annonc/​annonc741.CrossRef
6.
Gogishvili M, et al. Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC). In: Mini oral session – NSCLC, metastatic; September 19th, 2021. Presentation LBA51. Annals of Oncology 2021;32(suppl_5):S1283–346. https://​doi.​org/​10.​1016/​annonc/​annonc741.CrossRef
7.
Piccirillo MC. Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial. In: Proffered Paper session – NSCLC, metastatic 1; September 18th, 2020. Presentation 12070. Annals of Oncology 2021;32(suppl_5):S949–1039. https://​doi.​org/​10.​1016/​annonc/​annonc729.CrossRef
8.
Saito H, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. LancetOncolol. 2019;20(5):625–35.
9.
Maemondo M, et al. NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations. JCO Clin Cancer Inform. 2020;38(15suppl):9506.
10.
Soo R. A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial. In: Virtual Plenary Debate; September 17th, 2021; Abstract VP3_2021.
11.
Kenmotsu H, et al. Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study. In: Proffered Paper session – NSCLC, metastatic; September 18th, 2021. Presentation LBA44. Annals of Oncology 2021;32(suppl_5):S1283–346. https://​doi.​org/​10.​1016/​annonc/​annonc741.CrossRef
Metadata
Title
Highlights ESMO 2021—lung cancer
Author
Dr. Markus Rauter
Publication date
14-04-2022
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 2/2022
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00801-0

Other articles of this Issue 2/2022

memo - Magazine of European Medical Oncology 2/2022 Go to the issue

short review

Antibody–drug conjugates—the magic bullet?

short review

Agony of choice—selecting chronic lymphocytic leukemia treatment in 2022

case report

Immunotherapy pitfall: sarcoid-like reaction mimicking disease progression in advanced melanoma treated with nivolumab

short review

Breast Cancer—Essential news of current guidelines

editorial

New targeted therapies/small molecules in oncology and hematology

short review

ESMO 2021—my top three abstracts in breast cancer

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits